Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Fineline Cube May 18, 2026
Company Drug

Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy

Fineline Cube May 18, 2026
Company Deals

Luye Pharma Expands Latin American Reach with Exclusive Seroquel Promotion Agreement in Brazil and Mexico

Fineline Cube May 14, 2020

Luye Pharma Group (HKG: 2186), a leading Chinese pharmaceutical conglomerate, has declared that its wholly-owned...

Company Drug

Zai Lab’s Optune Approved by China’s NMPA, Offering New Hope for Glioblastoma Patients

Fineline Cube May 14, 2020

Zai Lab Ltd (NASDAQ: ZLAB), a biopharmaceutical company based in China, has received approval from...

Policy / Regulatory

Enhancing Clinical Trial Success: CDE’s New Adaptive Design Framework Opens for Comment

Fineline Cube May 14, 2020

The newly proposed guidelines are designed to be applicable across a spectrum of confirmatory clinical...

Company

Thermo Fisher Scientific Develops Serology Test to Detect COVID-19 Antibodies in Collaboration with WuXi Diagnostics and Mayo Clinic

Fineline Cube May 14, 2020

Thermo Fisher Scientific Inc., a titan in the US device industry and listed on the...

Company

Cuban-Chinese Pharma Synergy: Joint R&D and Sales Initiative Targets USD 24.53 Billion in Sales

Fineline Cube May 14, 2020

In a significant move to bolster its innovation pipeline, Guangzhou Pharmaceutical Holdings Ltd. has entered...

Deals

Guangzhou Pharma and BioCubaFarma Chart New Course with Joint Biologics R&D and Exchange Deal

Fineline Cube May 14, 2020

Guangzhou Pharmaceutical Holdings Ltd., a prominent player in China’s pharmaceutical sector, has inked a strategic...

Company Drug

Hanx Biopharmaceuticals’ HX009 Receives NMPA Clinical Trial Approval for PD-1/CD47 Bispecific Antibody

Fineline Cube Nov 4, 2019

China-based Hanx Biopharmaceuticals Co., Ltd has announced that its self-developed anti PD-1/CD47 bispecific antibody drug,...

Company

LanssonPharm Secures Series A Funding to Accelerate CNS Drug Development

Fineline Cube Jan 28, 2019

LanssonPharm, a company dedicated to the development of central nervous system (CNS) drugs, has announced...

Hospital

China’s Ministry of Health Tightens Organ Transplant Regulations with Expert Conference

Fineline Cube Apr 4, 2007

Shi Bingyi, a distinguished Member of the National Committee of the CPPCC (Chinese People’s Political...

R&D

China Launches Unprecedented Multi-Center Hypertension Study with Global Implications

Fineline Cube Apr 4, 2007

On April 2nd, a landmark healthcare initiative, the “Hypertension Prevention and Treatment Research” project, commenced...

Company

China Biopharma Posts 216% Revenue Increase, Eyes US$10 Million in 2007 with Vaccine Distribution and New Treatments

Fineline Cube Apr 4, 2007

China Biopharma Corporation, trading on the OTC Bulletin Board under the symbol (CBPC.OB), announced a...

Policy / Regulatory

Shanghai to Launch China’s Largest ADR Database, Enhancing Pharmaceutical Oversight

Fineline Cube Apr 4, 2007

Shanghai is advancing towards a significant milestone in pharmaceutical safety with plans to establish the...

Policy / Regulatory

China Unveils TCM Development Guidelines: A Strategic Defense of Traditional Medicine

Fineline Cube Apr 4, 2007

In a strategic move to assert the value and historical significance of Traditional Chinese Medicine...

Company

India Launches Anti-Dumping Campaign Against Chinese Vitamin B12 and Ceftriaxone Sodium Producers

Fineline Cube Apr 4, 2007

In a strategic response to India’s Ministry of Commerce and Industry’s (MOFCOM) anti-dumping ruling against...

Company

Novartis Sees 15% Global Sales Growth and Significant Investment in China for 2006

Fineline Cube Apr 4, 2007

Novartis (NYSE: NVS), a multinational pharmaceutical giant, has reported a robust sales revenue of nearly...

Hospital R&D

Ruijin Hospital Researchers Uncover Five New Mutations in Rare 17OHD Endocrine Disorder

Fineline Cube Apr 4, 2007

In a significant advancement in endocrine research, scientists within the Endocrine Department at Ruijin Hospital...

Policy / Regulatory

China’s SFDA Mandates Official Position Rotation to Boost Transparency

Fineline Cube Apr 4, 2007

China’s State Food and Drug Administration (SFDA) is poised to embrace a new era of...

Policy / Regulatory

Guangdong’s ‘Sunlight Purchase’ System Sparks Drug Pricing War and Uncovers Pricing Anomalies

Fineline Cube Apr 4, 2007

Since 2007, Guangdong province’s medical facilities have utilized an online procurement system known as “Sunlight...

Hospital R&D

Ruijin Hospital Unveils Five New Mutations in Rare Adrenal Hyperplasia Study

Fineline Cube Apr 4, 2007

In a groundbreaking study, Ruijin Hospital’s Endocrine Department researchers identified five novel mutations in 17...

Policy / Regulatory

SFDA Embraces Transparency: Regular Press Briefings and Personnel Rotations Announced

Fineline Cube Apr 4, 2007

China’s State Food and Drug Administration (SFDA) is gearing up for a transparency overhaul, with...

Posts pagination

1 … 665 666 667

Recent updates

  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
  • Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy
  • Shanghai CureGene’s CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial – First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance
  • Shenzhen Salubris Secures Chinese Approval for Xinfutai Plus – First Once-Weekly Teriparatide for High-Risk Postmenopausal Osteoporosis
  • Changchun GeneScience’s GenSci161 Receives FDA Clearance for Hidradenitis Suppurativa Clinical Trial – Novel Bispecific Antibody Targeting IL-1α/IL-1β
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Company Drug

Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy

Company Drug

Shanghai CureGene’s CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial – First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance

Company Drug

Shenzhen Salubris Secures Chinese Approval for Xinfutai Plus – First Once-Weekly Teriparatide for High-Risk Postmenopausal Osteoporosis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.